South & Central America Pharmaceuticals Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The South & Central America Pharmaceuticals Market size is expected to reach US$ 95.3 Billion by 2031 from US$ 69.3 Billion in 2024. The market is estimated to record a CAGR of 4.5% from 2025 to 2031.

Executive Summary and South & Central America Pharmaceuticals Market Analysis:

The pharmaceuticals market in South & Central America is segmented into Brazil, Argentina, and the rest of South & Central America. The market growth in this region is attributed to a large population, expanding healthcare infrastructure, soaring government focus on healthcare innovation, rising healthcare expenditure, and increased demand for treatments due to the rising prevalence of chronic diseases.

Countries in South & Central America, particularly Costa Rica and Brazil are becoming popular destinations for medical tourism due to their high-quality healthcare services and affordable costs. The growth of medical tourism has led to an increase in the demand for pharmaceuticals as patients from around the world seek treatment in these countries. The rise in elective surgeries, cosmetic procedures, and specialized treatments has increased the demand for medications. Brazil boasts numerous JCI-accredited hospitals and clinics, ensuring that international patients receive care that meets the highest global standards. The state of Pernambuco, particularly its capital Recife, ranks as the second-largest medical tourism hub in Brazil, boasting over 2,000 healthcare centers. According to the Research Sector of the Pernambuco Department of Tourism and Leisure, more than 120,000 tourists visited Recife for medical treatment in 2022.

South & Central America Pharmaceuticals Market: Strategic Insights

South & Central America Pharmaceuticals Market Segmentation Analysis:

• By Molecule Type, the South & Central America Pharmaceuticals Market is segmented into Small Molecule and Biological and Biosimilar Products. Small Molecule held the largest share of the market in 2024.
• By Indication, the South & Central America Pharmaceuticals Market is segmented into Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Disease, and Others. Cancer held the largest share of the market in 2024.
• By Product, the South & Central America Pharmaceuticals Market is segmented into Branded and Generic. Branded held the largest share of the market in 2024.
• By Type, the South & Central America Pharmaceuticals Market is segmented into Prescription and OTC Drugs. Prescription held the largest share of the market in 2024.
• By Distribution Channel, the South & Central America Pharmaceuticals Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies held the largest share of the market in 2024.

South & Central America Pharmaceuticals Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Pharmaceuticals Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South & Central America Pharmaceuticals Market Outlook

Emerging regional powers will redefine pharma dominance, shifting innovation and market focus beyond traditional hubs. Supply chains will diversify strategically to reduce dependency and boost agility amid global uncertainties. Regulatory frameworks will evolve rapidly, embracing digital tools and cross-border collaboration for streamlined approvals. This triad will transform the pharmaceutical sector into a more decentralized, resilient, and innovation-driven ecosystem. As per Oxford Economics, the global Pharmaceuticals Market, valued at US$1.5 trillion in 2023, is on a steady growth path, with projected expansion of 3% in 2024, 4% in 2025, and 3.6% in 2026, shaped by evolving healthcare needs, supply chain shifts, and regulatory changes. The pharmaceutical industry is undergoing a fundamental transformation driven by shifting global power dynamics, supply chain diversification, and evolving regulations. Increasing demand for specialized medicines and intensified mergers and acquisitions are reshaping the competitive landscape. Challenges such as regulatory complexity and cost pressures persist, requiring greater agility and innovation. Localization and resilience in supply chains are becoming strategic priorities. Overall, the market's future will be defined by adaptability to geopolitical, technological, and healthcare shifts worldwide.

South & Central America Pharmaceuticals Market Country Insights

By country, the South & Central America Pharmaceuticals Market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest share in 2024.

In Brazil, the Pharmaceuticals Market holds considerable potential owing to its large population, expanding healthcare infrastructure, and growing government focus on healthcare innovation. According to ITA, Brazil allocates 9.47% of its GDP to healthcare, equivalent to US$161 billion. The Brazilian Federation of Hospitals (FBH) and the National Confederation of Health (CNSaúde) report that out of 7,191 hospitals in the nation, 62% are private. As of 2022, the country had 427,097 hospital beds (FBH), 710 health insurance providers (Agência Nacional de Saúde - ANS), 546,000 physicians (Conselho Federal de Medicina - CFM), 402,000 dentists (Conselho Federal de Odontologia - CFO), and 90,900 drugstores (Associação Brasileira de Distribuição e Logística de Produtos Farmacêuticos - Abradilan). In 2022, pharmaceutical sales reached US$20.67 billion, marking a 26.2% increase from 2021.

According to the Pan American Health Organization, Brazil had more than 30 Billion older adults aged 60 and above as of 2022, indicative of 13% of the country's population. By 2030, the number of people from this age group will reach nearly 50 Billion, which will be 24% of its total population. The WHO and the Brazilian Institute of Geography and Statistics reported that the geriatric population in Brazil (i.e., aged?60 and older) is expected to reach ~55 Billion by 2040. According to GLOBOCAN 2022, there were 627,193 cancer cases across the country, comprising 319,711 males and 307,482 women. Brazil has a high incidence of cancer, and drugs could significantly reduce the disease's burden, benefiting from global innovations and the nation's unique epidemiological landscape. Additionally, as the country's healthcare professionals become more familiar with the concept of personalized medicine and targeted therapies, the demand for therapeutic vaccines is expected to increase in the coming years. This growing knowledge base, coupled with rising public interest in novel medical treatments, opens up new opportunities for vaccine development and commercialization.

South & Central America Pharmaceuticals Market Company Profiles

Some of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Viatris Inc, Sanofi SA, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, Eli Lilly and Co, Hikma Pharmaceuticals Plc, UCB SA, and ESTEVE.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South & Central America Pharmaceuticals Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise